Last reviewed · How we verify
Non-selective beta-blockers
At a glance
| Generic name | Non-selective beta-blockers |
|---|---|
| Also known as | Carvedilol, Propranolol, NSBBs |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis (PHASE2)
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (PHASE3)
- Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator (PHASE4)
- Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial (NA)
- Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors
- Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss (NA)
- A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-selective beta-blockers CI brief — competitive landscape report
- Non-selective beta-blockers updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI